A five-year, up-to-$29.6 million research consortium will develop living cardiac tissues for infants and young children with ...

On Thursday, the FDA granted full approval to Humacyte, Inc.'s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...

Humacyte, a bioengineering company, went public through a SPAC merger in 2015, with a market value of $1.1 billion. The company has received FDA's RMAT designation for three indications, including ...

Xylyx Bio, Inc., a regenerative medicine company developing bioengineered technologies for organ transplantation, tissue ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The FDA granted a Priority Review in February 2024 and was assigned a PDUFA date of August 10, 2024. ATEV is a bioengineered human tissue designed to be a universally implantable vascular conduit for ...

Bioengineered organs are no longer just structural substitutes. A review published in Trends in Biotechnology introduces a groundbreaking concept: biohybrid-engineered tissue (BHET) platforms—living ...

Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 ...

A new bioengineered neuronal circuit board "BioConNet" allows scientists to artificially engineer human brain-like wiring at scale and can be used to engineer any possible circuit. The fully ...

Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model to carry out vital cancer research, offering new insights into potential therapies for the ...

A new type of bioengineered blood vessel has shown strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...